PellePharm

About:

PellePharm develops patidegib, a novel hedgehog pathway inhibitor to mitigate the tumor burden in patients with basal cell carcinomas.

Website: http://pellepharm.com

Top Investors: BridgeBio

Description:

PellePharm develops patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in phase 2 clinical trial for the treatment of sporadic BCCs.